Thermo Fisher Scientific TMO has been making significant moves in the bio-tech market recently, securing a
$94.5 Million U.S. Government Contract to supply the Navy with advanced radiation detection systems, which considerably propels its position in the market. Also, it has been proclaimed amongst
Billionaire Ken Fisher's and
Mario Gabelli's Health Care Stock Picks which have a massive upside potential. Barclays and several market analysts have revised and reduced Thermo Fisher's price target amidst its second-quarter outlook. The firm has shown resilience while facing market corrections and even revealing the possibility of selling parts of its Diagnostics business. Thermo Fisher is being valued for introducing
next-generation mass spectrometers and expanding its mRNA collaboration, which could revolutionize Biopharma applications and Omics research. Despite facing tariff hits and cuts in research funding, Thermo Fisher has excitingly anticipated robust profit gains in 2025. Its recent launch of the
5L DynaDrive single-use bioreactor may simplify process development, potentially speeding up the delivery of new therapies.
Thermo Fisher Scientific TMO News Analytics from Thu, 07 Nov 2024 08:00:00 GMT to Fri, 27 Jun 2025 15:38:13 GMT -
Rating 7
- Innovation 8
- Information 6
- Rumor 1
